Wedbush Maintains Outperform on Janux Therapeutics, Lowers Price Target to $36
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst Robert Driscoll maintains Janux Therapeutics (NASDAQ:JANX) with a Outperform and lowers the price target from $45 to $36.
Wedbush analyst Robert Driscoll maintains Janux Therapeutics (NASDAQ:JANX) with a Outperform and lowers the price target from $45 to $36.